Andere talen Roivant Sciences Ltd.

Aandelen

ROIV

BMG762791017

Vertraagde tijd Nasdaq Andere beurzen 22:00:00 18-06-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
10,84 ^USD	+1,12%		+2,55%	-3,47%

10/06	Transcript : Roivant Sciences Ltd. Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-10-2024 08:40 AM
05/06	Transcript : Roivant Sciences Ltd. Presents at Jefferies 2024 Global Healthcare Conference, Jun-05-2024 11:30 AM

Andere talen

Krijg toegang tot al het nieuws: wees als eerste op de hoogte en reageer voordat de beurs dat doet!

Gratis inschrijven

Roivant Sciences Ltd. Reports Earnings Results for the Full Year Ended March 31, 2024	30/05
Roivant Sciences : 4Q2023 Earnings Call Presentation	30/05
Roivant Sciences' Fiscal Q4 Net Loss Widens, Revenue Rises	30/05
Futures Decline Pre-Bell as Traders Await Key Economic Reports; Asia Down, Europe Rises	30/05
Roivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2024, and Provides Business Update	30/05
Roivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2024, and Provides Business Update	30/05
Roivant Sciences Ltd. Reports Earnings Results for the Fourth Quarter Ended March 31, 2024	30/05
Roivant to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2024, and Provide Business Update on Thursday, May 30, 2024	16/05
Arbutus Biopharma Obtains Favorable Court Order in Moderna Patent Lawsuit	05/04
Moderna Suffers Setback in Lawsuit by Arbutus	04/04
Moderna shares fall after judge sides with Arbutus in patent fight	03/04
Tesla, UnitedHealth Group fall; Roivant, Valero rise, Tuesday, 4/2/2024	02/04
Roivant Sciences : NIU Phase 2 Topline Results	02/04
Roivant Sciences Says Study of Potential Uveitis Treatment Meets Endpoints; Launches Stock Repurchase; Shares Rise	02/04
Roivant Sciences Ltd. announces an Equity Buyback for $1,500 million worth of its shares.	02/04
Roivant Announces Positive NEPTUNE Study Results for Brepocitinib in NIU, as well as Board Authorization for up to $1.5 Billion Share Repurchase Program, Including Repurchase of Entire Sumitomo Pharma Stake for $648 Million	02/04
Roivant's anti-inflammatory drug succeeds in mid-stage study	02/04
Roivant and Priovant Therapeutics Announce Positive Results from the Phase 2 Study for Brepocitinib in NIU	02/04
Roivant Sciences Ltd. authorizes a Buyback Plan.	02/04
Roivant Sciences Ltd.(NasdaqGS:ROIV) added to S&P 1000	01/04

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Roivant Sciences Ltd.

Aandelen

ROIV

BMG762791017

Andere talen

Filters